CurrentAetnaPolicy 0377

Dendritic Cell Immunotherapy - CPB-0377

Aetna Clinical Policy Bulletin (Number 0377) addressing dendritic cell (DC) immunotherapy for treatment of malignancies; states Aetna's coverage position and summarizes background evidence and applicability. Includes lists of related policies and ICD-10 codes referenced and policy history dates.

Policy Summary

PayerAetna

PolicyDendritic Cell Immunotherapy - CPB-0377

Policy CodePolicy 0377

Change TypeNo material change recorded

Effective DateFeb 1, 2000

Next Review DateApr 11, 2024

Key ActionClaims for dendritic cell immunotherapy should be adjudicated as experimental/investigational and not covered for the listed malignancy indications per this policy bulletin.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes — policy remains an experimental/investigational position with no new coverage changes documented.

1Coverage stance (experimental/investigational)

2000-02-01Effective date

2023-06-06Last review

2024-04-11Next review

Coverage Summary

Aetna Clinical Policy Bulletin Number: 0377 addresses dendritic cell (DC) immunotherapy for treatment of malignancies. Aetna considers dendritic cell immunotherapy experimental and investigational and not covered because the peer‑reviewed medical literature does not support its clinical use at this time. Policy effective date: 2000-02-01; Last review: 2023-06-06; Next review scheduled: 2024-04-11.

Key facts

Effective date2000-02-01

Last review2023-06-06

Next review2024-04-11

Coverage stanceExperimental / Investigational - Not Covered

Medical Necessity / Coverage Determination

Coverage Determination

Aetna considers dendritic cell immunotherapy experimental and investigational because the peer-reviewed medical literature does not support its clinical use at this time.

Dendritic cell immunotherapy is considered experimental and investigational

Rationale: peer-reviewed medical literature does not support its clinical use at this time

Coding — Not Covered

ICD-10 codes listed in policy as not covered for indications in this CPBICD-10Not Covered

C00.0-C43.9	Malignant neoplasms [leukemia, lymphoma, melanoma, solid tumors] (range as listed)
C44.0-C75.9	Malignant neoplasms (range as listed)
C76.0-C86.6	Malignant neoplasms (range as listed)
C88.4-C94.32	Malignant neoplasms (range as listed)
C94.80-C96.4	Malignant neoplasms (range as listed)
C96.6-C96.9	Malignant neoplasms (range as listed)
D03.0-D03.9	Melanoma in situ (range as listed)

CPT / HCPCS - Dendritic cell immunotherapymixedNot Covered

No specific code

No specific CPT/HCPCS code listed for dendritic cell immunotherapy in this part of the policy

Provider Actions / Adjudication Notes

Denial Risk

Use of policy for claim adjudication

Claims for dendritic cell immunotherapy should be adjudicated as experimental/investigational and not covered for the listed malignancy indications per this policy bulletin.

Documentation Required

Reference policy and review dates

Providers should reference the Aetna Clinical Policy Bulletin for dendritic cell immunotherapy (CPB) and note the policy effective date 2000-02-01, last review 2023-06-06, and next review scheduled 2024-04-11 when verifying coverage rules and prior authorization requirements.

Background and Evidence Summary

Dendritic cell immunotherapy uses patient‑derived dendritic cells — the most potent antigen‑presenting cells — isolated from blood or bone marrow, exposed ex vivo to tumor antigens, and reinfused as a therapeutic cancer vaccine to activate T‑lymphocytes. Clinical evaluation in humans is in early phases across malignancies (including leukemia, lymphoma, melanoma, and certain solid tumors) and available reports are largely anecdotal or early‑phase. Although DC vaccines can induce immune responses, completion of randomized trials is necessary because efficacy has not been established and key parameters such as appropriate antigen(s), adjuvant(s), dose, route, and schedule remain unestablished.

Study / Evidence	Key findings
HGG-2006 trial (Ardon et al. 2012)	Feasible with no major toxicity; 6-month PFS 70.1%; median OS 18.3 months; authors concluded DC vaccination integrated into standard post-op radiochemotherapy seems safe and possibly beneficial but randomized trials were needed.
Systematic review - ovarian cancer (Tanyi et al. 2012)	DC vaccines induced anti-tumor responses in models and were clinically safe with limited human trial results; clear therapeutic role in ovarian cancer remains to be clarified.
Systematic review - glioblastoma (Bregy et al. 2013)	Review of 21 studies (403 patients) found autologous tumor-loaded DC vaccination associated with increased median OS in recurrent and newly diagnosed GBM versus historical averages; authors called for larger trials.
Systematic review/meta-analysis - malignant gliomas (Wang et al. 2014)	Included comparative trials; immunotherapy was associated with significantly longer OS and 2-year survival compared to conventional therapy.
Systematic review/meta-analysis - DC-CIK therapy (Chen et al. 2014)	Pooled RCTs (n=6) showed chemotherapy + DC-CIK increased 2- and 3-year survival and PFS in non-small cell lung cancer; therapy appeared well-tolerated but further trials needed.
Systematic review/meta-analysis - HCC (Chen et al. 2018; Cao et al. 2019)	Meta-analyses reported DC-based therapy improved immune markers, PFS/OS rates and was safe, but cautioned due to small study numbers, heterogeneity and potential bias.
Meta-analyses in GI, pancreatic, gastric cancers (Liu 2019; Du 2020; Wang 2018)	Multiple meta-analyses of DC and DC-CIK therapies reported improved OS, PFS, response rates and immune markers with low severe adverse events; authors note heterogeneity and need for standardized, randomized trials.
Systematic review - DC therapy vs bevacizumab+irinotecan (Artene et al. 2016)	Survival gain analysis in recurrent malignant glioma found no significant difference in survival gain between DC vaccination and bevacizumab+irinotecan groups.
Comprehensive review/meta-analysis - glioma (Shamshiripour et al. 2022)	DC therapy showed acceptable safety (mostly grade I/II AEs) and immunologic activity (tumor CD8+ infiltration, IFN-γ increase) but diversity of response criteria and limited survival data limit firm conclusions.
References list (selected clinical and review literature)	Multiple cited trials and reviews (refs 1-65) document clinical studies, phase I/II trials, and systematic reviews of DC immunotherapy across tumor types; overall evidence is heterogeneous and insufficient to establish routine clinical use.

Policy Dates & Revision History

2000-02-01Effective date

Policy effective date

2023-06-06Last reviewLatest

Last review of policy